2 completed, 1 unknown, 1 withdrawn. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
Follow Clofazimine: new trials by email Literature Review of Clofazimine trials Research Report on Clofazimine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China Bedaquiline, Levofloxacin, Linezolid - Tuberculosis, Multidrug-Resistant | Phase 4 | Unknown | Beijing Chest Hospital | 212 | 2022-05-10 | 2023-01-18 |
| Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy Clofazimine, Placebo - Borderline Lepromatous Leprosy, Lepromatous Leprosy | Phase 4 | Completed | Paul Saunderson | 100 | 2010-08-01 | 2015-06-04 |
| Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Rifabutin, Clarithromycin, and Clofazimine - Crohn's Disease | Phase 4 | Withdrawn | Medstar Health Research Institute | 2007-07-01 | 2020-08-20 | |
| Uniform Multidrug Therapy Regimen for Leprosy Patients PB 6 doses - Rifampicin and Dapsone, PB 6 doses - Rifampicin, Clofazimine and Dapsone, MB 12 doses - Rifampicin, Clofazimine and Dapsone - Leprosy | Phase 4 | Completed | University of Brasilia | 859 | 2007-02-01 | 2017-06-01 |
Leprosy (2) · Communicable Diseases (1) · Crohn Disease (1) · Leprosy, Lepromatous (1) · Skin Diseases (1) · Tuberculosis, Multidrug-Resistant (1)
Beijing Chest Hospital (1) · Medstar Health Research Institute (1) · Paul Saunderson (1) · University of Brasilia (1)
Brazil (1) · China (1) · Philippines (1)
Gerson O Penna, MD, PhD (1) · Marivic Balagon, MD (1) · Mengqiu Gao (1) · Samira Buhrer, PhD (1) · Timothy R Koch, MD (1)
PMID 28222139, PMID 28704363, PMID 29867930, PMID 38561815, PMID 38697216, PMID 41925982